ACOD1 and cancer: One may hypothesize that the change to Met154 in human ACOD1, reducing itaconic acid synthesis, could contribute to a higher resistance against cancer, whereas the frequent Asn152Lys variant counteracts this reduction of enzyme activity, potentially improving host defence against infections.